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to the multivariate regression analysis, initial %fPSA value 
was not predictive for treatment change or adverse rebiopsy 
findings. However, the probability of discontinuing AS 
was significantly lower in patients with “favourable” initial 
%fPSA characteristics and %fPSA during follow-up (ini-
tial %fPSA ≥15 and positive %fPSA velocity) compared to 
those with “adverse” %fPSA characteristics (initial %fPSA 
<15 and negative %fPSA velocity).
Conclusions Diagnostic %fPSA provides no additional 
prognostic value when compared to other predictors 
already in use in AS protocols. However, %fPSA velocity 
during surveillance may aid in predicting the probability 
for future treatment change.
Keywords Prostate cancer · Active surveillance · 
Prostate-specific antigen · Free prostate-specific antigen
Introduction
With PSA testing being part of daily clinical practice, the 
issue of overdiagnosis and overtreatment of prostate cancer 
(PC) becomes more relevant. The number of likely over-
diagnosed low-risk cancers has increased dramatically and 
constitutes about one half of the newly diagnosed cases 
[1]. Active surveillance (AS) is a management option to 
consider in men with a diagnosis of localized low-risk PC 
instead of immediate curative treatment [2].
The aim of AS is to prevent or postpone treatment of a 
low-risk PC to alleviate side effects inherent to all contem-
porary radical PC treatments. The challenge is not only to 
correctly classify cancers to low-risk category, but also to 
be able to find PCs, that were initially miss-classified or are 
likely to progress, in a timely fashion. Current AS protocols 
utilize tools such as serial PSA measurements, digital rectal 
Abstract 
Purpose To evaluate the utility of percentage of free 
serum PSA (%fPSA) as a predictor of adverse rebiopsy 
findings, treatment change and radical prostatectomy (RP) 
findings in a prospective active surveillance (AS) trial.
Methods Patients enrolled in the global PRIAS study with 
baseline %fPSA available were included. Putative baseline 
predictors (e.g. PSA, %fPSA) of adverse rebiopsy findings 
were explored using logistic regression analysis. Associa-
tion of variables with treatment change and RP findings 
over time were evaluated with Cox regression analysis. 
Active treatment-free survival was assessed with a Kaplan–
Meier method.
Results Of 3701 patients recruited to PRIAS, 939 had 
%fPSA measured at study entry. Four hundred and thirty-
eight of them had %fPSA available after 1 year. Median 
follow-up was 17.2 months. First rebiopsy results were 
available for 595 patients and of those, 144 (24.2 %) had 
adverse findings. A total of 283 (30.1 %) patients discon-
tinued surveillance, of those 181 (64.0 %) due to protocol-
based reasons. Although median %fPSA values were signif-
icantly lower in patients who changed treatment, according 
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examination (DRE) and rebiopsies, but these clearly lack 
performance as demonstrated by the relatively high propor-
tion (24–46 %) of patients referred to active therapy [3–7]. 
Therefore, new tools such as multiparametric MRI, MRI-
ultrasound fusion [8, 9] and novel biomarkers are topic of 
ongoing urologic research [10]. Multiparametric MRI and 
MRI-ultrasound fusion were also added to the PRIAS study 
program in 2014.
Previous studies have shown that %fPSA (free/total PSA 
ratio in percentages) in serum has predictive value both at 
diagnosis and with radical prostatectomy (RP) outcome 
[11–13]. Also, PSA measurements over time (PSA kinet-
ics) have shown predictive power beyond a single PSA 
measurement in providing a more dynamic picture of PC 
activity and tumour behaviour [14]. Here, we hypothesize 
that %fPSA has a predictive role in AS. Specifically, we 
want to address whether %fPSA value at diagnosis or dur-
ing follow-up associates with adverse rebiopsy or RP find-
ings and whether treatment change can be predicted.
Patients and methods
Study patients participated in the international prospective 
AS study named Prostate Cancer research International: 
Active Surveillance (PRIAS) [15]. PRIAS inclusion criteria 
are PC diagnosis, PSA ≤10 ng/mL, tumour(T)-stage ≤2, 
PSA density (PSA-D) <0.2 ng/mL/cc, maximum two posi-
tive biopsies and Gleason score ≤6 (3 + 3). A candidate 
for AS should also be fit for radical treatment. Patients are 
monitored carefully; PSA is measured every 3 months and 
DRE is performed every 6 months during the first 2 years. 
After 2 years, PSA is measured every 6 months and DRE 
is performed yearly. Repeat biopsies are taken 1, 4 and 
7 years after inclusion. Biopsies are taken under TRUS 
guidance, and a prostate volume-dependent number of 
biopsy cores is advised. PSA doubling time (PSA-DT) is 
calculated yearly, and if it is 3–10 years, rebiopsy is rec-
ommended. Criteria for the advice to switch to active treat-
ment are PSA-DT <3 years, clinical T-stage >2, PC in more 
than two biopsy cores and/or Gleason score >6 (3 + 3).
fPSA measurement is not mandatory as a part of the 
PRIAS protocol, but in some participating centres, it was 
routinely measured. %fPSA values measured at study entry 
and at 1 year were available for statistical analysis. The RP 
data used in analyses were available from the Finnish arm 
of the PRIAS study.
PSA density (PSA-D) was calculated as total PSA (ng/
mL) divided by prostate volume (cc) at diagnosis. Clini-
cal stage T2 was not divided into subgroups due to the 
low number of cases. PSA-DT was divided into three cat-
egories: PSA-DT negative/>10 years, PSA-DT 3–10 years 
and PSA-DT <3 years. %fPSA velocity was the difference 
between %fPSA values at 1 year and diagnosis. For sub 
analyses, the population was stratified into four categories: 
(1) diagnostic %fPSA ≥15 and positive %fPSA velocity, 
(2) Diagnostic %fPSA ≥15 and negative %fPSA veloc-
ity, (3) diagnostic %fPSA <15 and positive velocity and 
(4) %fPSA <15 and negative velocity. The cut-off value 
15 (%fPSA) was chosen, as being widely used in clinical 
practice.
Reclassification in rebiopsy was defined as Gleason sum 
>6 (3 + 3) and/or ≥3 PC positive biopsy cores. For this 
analysis, only the results of the first rebiopsy were used due 
to the small number of patients with both %fPSA and sec-
ond/third rebiopsy result available. Pathological stage T3 
and/or Gleason sum >6 (3 + 3) were considered adverse 
RP findings. Time to active treatment was calculated from 
the study inclusion to the date of discontinuation of AS. For 
analyses, only discontinuations due to protocol-based rea-
sons were included.
The Statistical Package for the Social Sciences (SPSS, 
version 19.0; IBM) was used for the data analysis. The cut-
off level of statistical significance was set at p < 0.05 in all 
tests. The p values were calculated using the Mann–Whit-
ney U test (for continuous variables) and –Chi-square test 
(for categorical variables). Assumed predictors for adverse 
rebiopsy findings were examined by binary logistic regres-
sion analysis. Baseline predictors of time to treatment 
and time to adverse RP findings were analysed using Cox 
regression analysis. The Kaplan–Meier method was used 
to describe protocol-based treatment-free survival with 
respect to initial %fPSA and %fPSA velocity.
The ethics committee of each participating hospital 
approved the study protocol.
Results
Until October 2013, %fPSA was measured from 939 out 
of 3701 PRIAS patients at the study enrolment. These 939 
patients constitute the study cohort. %fPSA was also avail-
able in 438 patients after 1 year of AS. Median follow-up 
was 17.2 months (range 0.7–82.7). By the time of analysis, 
656 (69.9 %) patients of the study cohort were still on AS 
and 283 (30.1 %) had discontinued; of those, 181 (64.0 %) 
due to protocol-based reasons and 102 (36.0 %) because of 
other reasons such as anxiety, unknown reason or AS was 
changed to watchful waiting (WW). The median surveil-
lance until discontinuation for all reasons was 14.7 months 
(range 0.7–82.7) and 14.9 months (range 4.0–54.8) for 
protocol-based reasons. Overall, 153 (54.1 %) patients 
discontinued AS and underwent surgical radical treatment 
(i.e. open retropubic/robot-assisted laparoscopic prostatec-
tomy), 40 (14.1 %) had brachytherapy and 32 (11.3 %) had 
external beam radiotherapy. One (0.4 %) patient had HIFU 
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treatment, and in 19 (6.7 %) patients WW was initiated. A 
total of 38 (13.4 %) men had another treatment or the treat-
ment chosen was not available.
Characteristics of the patients enrolled in the study are 
summarized in Table 1. First rebiopsy results were avail-
able for 595 of the study patients and in 144 (24.2 %) PC 
reclassification occurred. According to the multivariate 
binary logistic regression analysis, the predicting vari-
ables for adverse first rebiopsy findings were the number 
of PC positive cores (one vs. two) at the diagnostic biopsy 
(p = 0.000) and age at diagnosis (p = 0.002) (Table 2). 
PSA and %fPSA could not predict PC reclassification.
In multivariate analysis, the initial %fPSA value was not 
predictive for treatment change. After 1 year of AS, the dif-
ference in median %fPSA values between patients still on 
surveillance (16.6 %) or discontinued (13.1 %) was statisti-
cally significant (p = 0.031). The probability to discontinue 
AS was significantly lower in patients with initial %fPSA 
value ≥15 and positive %fPSA velocity compared to 
those with initial %fPSA <15 and negative %fPSA veloc-
ity (p = 0.000) (Fig. 1). Cox regression analysis could 
not demonstrate an association between %fPSA and treat-
ment change over time, but did show this for PSA-D and 
the number of PC positive cores at the diagnostic biopsy 
(Table 3). According to Cox regression analysis, PSA-D 
(p = 0.028) was the only predictive baseline variable for 
unfavourable findings at RP (data not shown).
Discussion
The aim of the study was to evaluate the hypothesis 
that %fPSA has a role as a prognostic tool in AS. More 
specific, we wanted to address whether the %fPSA value 
at diagnosis or during follow-up associates with adverse 
rebiopsy or RP findings and whether treatment change can 
be predicted. Our results show that, although %fPSA val-
ues were statistically significantly different in the groups 
analysed (still on AS versus discontinued), no clinically 
relevant correlations of diagnostic %fPSA were evident to 
guide clinical practice. Interestingly, however, the prob-
ability of continuing AS was the highest in patients with 
favourable %fPSA characteristics at diagnosis and during 
follow-up.
Table 1  Characteristics of the patients enrolled in the study
25–75p 25th and 75th percentiles, PSA prostate-specific antigen, % fPSA free/total PSA ratio (%), PSA-D prostate-specific antigen density, NA 
not available
Variable All patients (n = 939) No treatment (n = 758) Active treatment (n = 181) p value
Age, year, median (25–75p) 64.9 (60.0–69.6) 65.2 (60.1–69.8) 64.4 (60.4–68.3) 0.290
Prostate vol, cm3, median (25–75p) 44.0 (34.9–54.0) 44.0 (35.0–55.0) 43.7 (33.5–52.0) 0.176
PSA, ng/mL, median (25–75p) 5.6 (4.5–7.0) 5.6 (4.5–6.8) 5.8 (4.8–7.3) 0.063
%fPSA, median (25–75p) 14.5 (9.7–18.8) 14.7 (10.1–19.7) 13.5 (8.6–18.6) 0.068
PSA-D, ng/mL/g, median (25–75p) 0.13 (0.10–0.16) 0.13 (0.10–0.16) 0.14 (0.11–0.17) 0.001
Clinical stage, no (%) 0.451
 T1c 863 (91.9) 699 (92.2) 164 (90.6)
 T2a–c 76 (8.1) 59 (7.8) 17 (9.4)
Biopsy cores median, no (25–75p) 12 (10–12) 12 (10–12) 12 (10–12) 0.004
Positive biopsy, no (%) 0.050
 1 649 (69.1) 534 (70.4) 115 (63.5)
 2 282 (30.0) 216 (28.5) 66 (36.5)
 NA 8 (0.9) 8 (1.1)
Table 2  Association of baseline characteristics with rebiopsy reclas-
sification
PSA prostate-specific antigen, % fPSA  free/total PSA ratio (%), PSA-
D prostate-specific antigen density, OR odds ratio, CI confidence 
interval
* Significant result (p < 0.05)
Baseline characteristics 1-year rebiopsy (n = 595) OR  
(95 % Cl)
p value
Age at dg 1.1 (1.02–1.09) 0.002*
PSA 0.96 (0.74–1.25) 0.79
%fPSA 1.0 (0.99–1.04) 0.41
PSA-D 1.1 (0.95–1.22) 0.26
Clinical stage 0.17
 T1c Ref.
 T2 1.62 (0.81–3.24)
Total Bx cores 0.98 (0.88–1.08) 0.64
Positive Bx cores 0.000*
 1 Ref.
 2 2.06 (1.38–3.09)
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While the strengths of our study are its prospective 
nature and the relatively large patient cohort, obvious short-
comings do exist. %fPSA was not routinely used, and thus 
only 25 % of the patients entering the entire PRIAS trial 
were available for the study and a bias can not be excluded. 
Also, short follow-up and lack of randomization comparing 
radical treatments of PC with AS make generalization of 
the results difficult.
%fPSA has been widely studied as a marker to predict 
the probability of PC diagnosis [11, 12]. The %fPSA has 
been used to stratify the risk of PC in men with the total 
PSA value between 4 and 10 ng/mL and a negative DRE 
finding. However, after PC diagnosis or PSA being more 
than 10 ng/mL, %fPSA has not been of clinical use. The 
association between low %fPSA and high-grade PC with 
aggressive features has been demonstrated previously [16, 
17], as well as the association between %fPSA and clini-
cally significant PC, based on analyses in a multivariate 
setting [18]. However, only a few studies have addressed 
the role of %fPSA as a prognostic tool in AS. Contradict-
ing our findings, previous studies have concluded that 
%fPSA predicts time to deferred radical treatment [5, 
19] or adverse rebiopsy results [19] in patients with low-
risk PC managed by AS. One explanation may be that 
PRIAS patients represent a relatively homogeneous patient 
cohort. In PRIAS, only minimal Gleason score 6 cancers 
are allowed as opposed to other trials where Gleason 7 
(3+4) cancers were also included, which likely increases 
the power of the analysis. Also, the used %fPSA cut-off, 
the definition of adverse rebiopsy findings and length of 
follow-up were all different hampering the comparability 
of the results. Importantly, only first rebiopsy results were 
used for the analysis in our study due to a limited number 
of patients with both %fPSA and later rebiopsy data avail-
able. It is likely that a change in Gleason score at rebiopsy 
at one year represent initial diagnostic misclassification 
instead of true disease progression. Therefore, longer fol-
low-up is needed to clarify the role of diagnostic %fPSA 
in AS. In multivariate analysis, PSA-D and the number 
of PC positive cores were the baseline characteristics that 
associated with treatment change. This is in concordance 
with the data from other AS cohorts [20, 21] and a recent 
PRIAS analysis [3] thus supporting the validity of the cur-
rent analysis.
Although baseline %fPSA could not predict treatment 
change, the median %fPSA at 1 year was significantly 
higher in patients able to continue AS than in patients that 
discontinued. The difference between the groups was par-
ticularly clear, if initial %fPSA and %fPSA velocity were 
used as a joined categorical variable. The probability of 
continuing AS was highest in men with favourable %fPSA 
initially and during follow-up. Literature on the utility of 
%fPSA velocity in AS is scarce. Although scepticism over 
PSA kinetics in general has been expressed [22], to our 
knowledge, %fPSA velocity has not been explored as a 
predictor of AS outcome before in the literature. However, 
a recent congress abstract supports the findings in our study 
[Heidegger I et al., EAU Milan, 2013]. Perhaps longitudi-
nal biomarker measurements (e.g. %fPSA-kinetics) may 
Fig. 1  Treatment-free survival of study patients stratified into sub-
groups based on %fPSA characteristics. 1 %fPSA ≥15 and  % fPSA 
velocity positive (blue), 2 %fPSA ≥15 and  %fPSA velocity nega-
tive (green), 3 %fPSA <15 and %fPSA velocity positive (yellow), 4 
%fPSA <15 and %fPSA velocity negative (purple), statistical differ-
ences between groups: p < 0.05, 1 versus 4; p ≥ 0.05, all other com-
parisons
Table 3  Cox regression analysis of baseline characteristics with 
treatment change (protocol-based) over time
PSA prostate-specific antigen, fPSA % free/total PSA ratio (%), PSA-
D prostate-specific antigen density, HR hazard ratio
* Significant result (p < 0.05)
Baseline characteristics Treatment change (n = 181) HR 
(95 % Cl)
p value
Age at dg 1.0 (0.97–1.02) 0.81
PSA 1.0 (0.94–1.14) 0.48
%fPSA 0.99 (0.88–1.20) 0.74
PSA-D 1.1 (1.01–1.11) 0.013*
Clinical stage 0.39
 T1c Ref.
 T2 1.3 (0.74–2.18)
Total Bx cores 1.0 (0.92–1.08) 0.92
Positive Bx cores 0.019*
 1 Ref.
 2 1.5 (1.07–2.01)
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have better predictive accuracy than a single baseline meas-
urement in AS programs [23]. Also serial biomarker meas-
urements over time provide greater potential to characterize 
the tumour more accurately than on the basis of a single 
baseline value. This is especially interesting in the light of 
recently published data suggesting that PSA velocity risk 
count (expressed as the number of times PSA velocity 
exceeds a certain threshold in a certain time period) is inde-
pendently associated with adverse rebiopsy findings in an 
AS cohort [24]. In our study, the baseline variables’ predic-
tive of adverse rebiopsy results was the number of positive 
biopsy cores and age, which is in line with the results from 
other AS series [3–7].
Our results showed no association between %fPSA and 
RP findings. The only predictive baseline variable was 
PSA-D, which has also been shown earlier [25]. Contrary 
to our findings, previous studies have demonstrated the pre-
dictive capability of %fPSA for significant cancer in RP. A 
low %fPSA has been associated with significant upgrading 
of low-grade PC after RP [13], adverse pathological fea-
tures following surgery [26] and higher stage in RP [27, 
28]. It is likely that the power needed for analyses is not 
reached in our study due to the small number of RPs done. 
Therefore longer follow-up and larger series are needed to 
clarify this issue.
In conclusion, diagnostic %fPSA alone provided no 
additional prognostic benefit when compared to other 
predictors used in AS protocols, such as PSA kinetics. 
However, %fPSA coupled to %fPSA velocity during may 
increase the ability to predict patients at risk to change 
treatment during AS.
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